Cover Image

Lenvantinib: a tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET

Lenvatinib is an oral receptor tyrosine kinase inhibitor (TKI) with activity against vascular endothelial growth factor (VEGF) receptors 1-3, fibroblast growth factor receptors (FGFR) 1-4, platelet-derived growth factor receptor-alpha (PDGFRα), and RET and KIT proto-oncogenes. Lenvatinib is approved...

Full description

Saved in:
Bibliographic Details
Main Authors: Zschäbitz, Stefanie (Author) , Grüllich, Carsten (Author)
Format: Chapter/Article
Language:English
Published: 02 August 2018
In: Small molecules in oncology
Year: 2018, Pages: 187-198
Online Access:Verlag: https://link.springer.com/chapter/10.1007%2F978-3-319-91442-8_13
Verlag: https://europepmc.org/article/med/30069768
Get full text
Author Notes:Stefanie Zschäbitz, Carsten Grüllich

MARC

LEADER 00000caa a22000002c 4500
001 1694063526
003 DE-627
005 20220818031332.0
007 cr uuu---uuuuu
008 200403s2018 xx |||||o 00| ||eng c
024 7 |a 10.1007/978-3-319-91442-8_13  |2 doi 
035 |a (DE-627)1694063526 
035 |a (DE-599)KXP1694063526 
035 |a (OCoLC)1341313731 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Zschäbitz, Stefanie  |d 1983-  |e VerfasserIn  |0 (DE-588)1037698827  |0 (DE-627)75589894X  |0 (DE-576)391727206  |4 aut 
245 1 0 |a Lenvantinib  |b a tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET  |c Stefanie Zschäbitz, Carsten Grüllich 
246 3 0 |a alpha one three four 
264 1 |c 02 August 2018 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 06.04.2020 
520 |a Lenvatinib is an oral receptor tyrosine kinase inhibitor (TKI) with activity against vascular endothelial growth factor (VEGF) receptors 1-3, fibroblast growth factor receptors (FGFR) 1-4, platelet-derived growth factor receptor-alpha (PDGFRα), and RET and KIT proto-oncogenes. Lenvatinib is approved for the treatment of radioiodine-refractory differentiated thyroid cancer and in combination with everolimus for the treatment of advanced renal cell carcinoma following anti-VEGF treatment. In hepatocellular carcinoma lenvatinib was non inferior to sorafenib in first line with an improved progression-free survival and approval in this indication is expected. Lenvatinib is currently investigated for further indications as single agent and in combinations. Side effects include typical TKI induced toxicities such as hypertension, diarrhea, hypothyroidism, and fatigue. 
650 4 |a Animals 
650 4 |a Antineoplastic Agents 
650 4 |a Differntiated thyroid cancer 
650 4 |a Hepatocellular carcinoma 
650 4 |a Humans 
650 4 |a Lenvantinib 
650 4 |a Neoplasms 
650 4 |a Phenylurea Compounds 
650 4 |a Protein Kinase Inhibitors 
650 4 |a Proto-Oncogene Proteins c-kit 
650 4 |a Proto-Oncogene Proteins c-ret 
650 4 |a Quinolines 
650 4 |a Receptor Protein-Tyrosine Kinases 
650 4 |a Receptor, Platelet-Derived Growth Factor alpha 
650 4 |a Receptors, Vascular Endothelial Growth Factor 
650 4 |a Renal cell carcinoma 
700 1 |a Grüllich, Carsten  |d 1965-  |e VerfasserIn  |0 (DE-588)14101914X  |0 (DE-627)624500985  |0 (DE-576)321797981  |4 aut 
773 0 8 |i Enthalten in  |t Small molecules in oncology  |b Third edition  |d Cham, Switzerland : Springer, 2018  |g (2018), Seite 187-198  |h 1 Online-Ressource (VIII, 276 Seiten)  |w (DE-627)1030110883  |w (DE-576)510624766  |z 9783319914428  |7 nnam  |a Lenvantinib a tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET 
773 1 8 |g year:2018  |g pages:187-198  |g extent:12  |a Lenvantinib a tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET 
856 4 0 |u https://link.springer.com/chapter/10.1007%2F978-3-319-91442-8_13  |x Verlag 
856 4 0 |u https://europepmc.org/article/med/30069768  |x Verlag 
951 |a AR 
992 |a 20200403 
993 |a BookComponentPart 
994 |a 2018 
998 |g 14101914X  |a Grüllich, Carsten  |m 14101914X:Grüllich, Carsten  |d 910000  |d 910100  |e 910000PG14101914X  |e 910100PG14101914X  |k 0/910000/  |k 1/910000/910100/  |p 2  |y j 
998 |g 1037698827  |a Zschäbitz, Stefanie  |m 1037698827:Zschäbitz, Stefanie  |d 910000  |d 910100  |e 910000PZ1037698827  |e 910100PZ1037698827  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1694063526  |e 3618669844 
BIB |a Y 
JSO |a {"relHost":[{"origin":[{"publisher":"Springer","dateIssuedDisp":"[2018]","publisherPlace":"Cham, Switzerland","dateIssuedKey":"2018","edition":"Third edition","editionNo":3}],"type":{"bibl":"edited-book","media":"Online-Ressource"},"language":["eng"],"relMultPart":[{"dispAlt":"Recent results in cancer research","pubHistory":["Nachgewiesen 165.2006 -"],"recId":"548128227","note":["Gesehen am 25.10.07"],"disp":"Recent results in cancer research","id":{"zdb":["2393522-4"],"eki":["548128227"],"issn":["2197-6767"]},"title":[{"title_sort":"Recent results in cancer research","title":"Recent results in cancer research"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"number_sort":["211"],"number":["volume 211"]},"type":{"bibl":"serial","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2006","publisherPlace":"Berlin ; Heidelberg","dateIssuedDisp":"2006-","publisher":"Springer"}],"language":["eng"]}],"physDesc":[{"noteIll":"Illustrationen","extent":"1 Online-Ressource (VIII, 276 Seiten)"}],"person":[{"display":"Martens, Uwe Marc","role":"edt","given":"Uwe Marc","roleDisplay":"HerausgeberIn","family":"Martens"}],"name":{"displayForm":["Uwe M. Martens, editor"]},"part":{"text":"(2018), Seite 187-198","year":"2018","extent":"12","pages":"187-198"},"recId":"1030110883","id":{"isbn":["9783319914428"],"eki":["1030110883"],"doi":["10.1007/978-3-319-91442-8"]},"title":[{"title_sort":"Small molecules in oncology","title":"Small molecules in oncology"}],"disp":"Lenvantinib a tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RETSmall molecules in oncology"}],"person":[{"given":"Stefanie","display":"Zschäbitz, Stefanie","role":"aut","family":"Zschäbitz","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Grüllich","given":"Carsten","role":"aut","display":"Grüllich, Carsten"}],"name":{"displayForm":["Stefanie Zschäbitz, Carsten Grüllich"]},"physDesc":[{"extent":"12 S."}],"type":{"media":"Online-Ressource","bibl":"chapter"},"origin":[{"dateIssuedDisp":"02 August 2018","dateIssuedKey":"2018"}],"language":["eng"],"note":["Gesehen am 06.04.2020"],"recId":"1694063526","title":[{"subtitle":"a tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET","title_sort":"Lenvantinib","title":"Lenvantinib"}],"id":{"doi":["10.1007/978-3-319-91442-8_13"],"eki":["1694063526"]}} 
SRT |a ZSCHAEBITZLENVANTINI0220 

Similar Items